CytomX Therapeutics Inc (CTMX) Actualités

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a...

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a...

Form 8-K - Current report

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a...

Form 8-K - Current report

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC...

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]